AbbVie has announced a $1.4-billion investment to build a new 185-acre pharmaceutical manufacturing campus in Durham, North Carolina. The investment is part of the company’s $100-billion, 10-year capital investment plan in the US, which includes R&D and manufacturing, which the company announced in January (January 2026). 

The campus will integrate manufacturing and laboratory technologies with artificial intelligence (AI) to support the production of AbbVie’s immunology, neuroscience, and oncology medicines. The first phase of construction will include small-volume parenteral drug-product manufacturing facilities, laboratories, a warehouse, administrative offices, and employee wellness facilities. Construction will begin this year (2026), with completion expected by the end of 2028. 

This campus will add to the company’s manufacturing footprint in the US, which includes AbbVie’s previously announced $380-million investment for two new active pharmaceutical ingredient (API) manufacturing facilities in North Chicago, Illinois. Construction of those facilities is expected to begin this spring (spring 2026) with both facilities expected to be fully operational in 2029. 

In the US, AbbVie has a presence in all 50 states and Puerto Rico and employs approximately 29,000 people in the US, including more than 6,000 at its US manufacturing campuses. With the announcement of the new North Carolina campus, AbbVie says it has committed to investing more than $2.2 billion in US manufacturing over the past 12 months (as reported on April 22, 2026).  

Source: AbbVie